Imunopharm Technology
Make the incurable curable
Beijing, China
19 employees
Venture round
Total: $262.50M
Biotechnology, Medical Devices +1
General Information
Beijing, China
BounceWatch is an independent company data service, not affiliated with Imunopharm Technology. To contact Imunopharm Technology, visit imunopharm.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Imunopharm Technology compare?
A PDF of Imunopharm Technology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Imunopharm Technology soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Imunopharm Technology on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
China Market
Biotechnology
About Imunopharm Technology
Business keywords: gene cell therapy, cancer treatment, innovation platform, clinical trials, CAR-T technology, immune cell preparation, oncology research, biopharmaceutical, disruptive technology, medical technology development, high-tech enterprise, immune cell therapy, pharmaceutical manufacturing, medical research, scale-up plasmid preparation
Funding Rounds & Investors (10)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | Undisclosed | 1 |
China Taiping Insurance
|
08 May 2023 |
| Series D | Undisclosed | 2 |
Zhongguancun Science City Science, Beijing Innovation Industry Investment
|
01 Nov 2022 |
| Series D | Undisclosed | 4 |
|
24 Nov 2021 |
| Series C | Undisclosed | - |
|
01 Dec 2020 |
| Series C | CNY100.00M | 1 |
Zhixing Ande Touzi
|
01 Oct 2020 |
| Series C | CNY140.00M | 5 |
|
22 Jan 2019 |
| Series B | $7.50M | 3 |
|
24 Nov 2017 |
| Series A | Undisclosed | - |
|
01 Mar 2016 |
| Seed Round | CNY10.00M | 1 |
Capital Technology Ventures
|
01 Dec 2015 |
| Seed Round | CNY5.00M | 1 |
|
01 Jun 2015 |
Imunopharm Technology Alternatives & Competitors
View All Alternatives
Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzym...
A biopharmaceutical company developing innovative cell therapy platforms for patients with cancer (N...
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personal...
IASO Biotechnology（驯鹿生物）
FAQ About Imunopharm Technology
Source: BounceWatch company record for Imunopharm Technology, https://bouncewatch.com/company/immunochina, updated 30 December 2024. When citing, please name BounceWatch and link this page.
